发明授权
- 专利标题: Phosphopeptides as melanoma vaccines
- 专利标题(中): 磷酸肽作为黑素瘤疫苗
-
申请号: US13318821申请日: 2010-05-04
-
公开(公告)号: US09279011B2公开(公告)日: 2016-03-08
- 发明人: Suzanne L. Topalian , Florence A Depontieu , Donald F. Hunt , Jeffrey Shabanowitz , Jie Qian , Victor H. Engelhard , Angela Lee Zarling
- 申请人: Suzanne L. Topalian , Florence A Depontieu , Donald F. Hunt , Jeffrey Shabanowitz , Jie Qian , Victor H. Engelhard , Angela Lee Zarling
- 申请人地址: US MD Baltimore US VA Charlottesville
- 专利权人: The Johns Hopkins University,University of Virginia Patent Foundation
- 当前专利权人: The Johns Hopkins University,University of Virginia Patent Foundation
- 当前专利权人地址: US MD Baltimore US VA Charlottesville
- 代理机构: Banner & Witcoff, LTD.
- 国际申请: PCT/US2010/033530 WO 20100504
- 国际公布: WO2010/129537 WO 20101111
- 主分类号: A61K39/00
- IPC分类号: A61K39/00 ; A61K47/00 ; C07K14/47 ; G01N33/574 ; C12Q1/68 ; A61K39/39
摘要:
We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DRβ1*0101-restricted CD4+ T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4+ T cells are potential targets for cancer immunotherapy.
公开/授权文献
- US20120177669A1 PHOSPHOPEPTIDES AS MELANOMA VACCINES 公开/授权日:2012-07-12
信息查询